Allergy Therapeutics PLC (AGY)

Industry Drug Manufacturers - Specialty & Generic

This stock can be held in an Investment ISA, SIPP and Investment Account

Sell

9.50p

Buy

11.00p

arrow-down-0.50p (-4.65%)

Prices updated at 12 Dec 2025, 16:09 GMT

Prices minimum 15 mins delay

Prices in GBX

Allergy Therapeutics PLC is a pharmaceutical products company. It develops therapies for allergy based diseases, having its primary market in Germany.

FTSE All-Share

-0.48%

LSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Chairman

Mr. Peter Sinclair Jensen

CEO

Mr. Manuel Llobet

Most recent earnings

30 Jun 2025

Fiscal year end

30 Jun 2025

Employees

576

Head office

Dominion Way

Worthing

United Kingdom

BN14 8SA

+44 1903844700

infoservices@allergytherapeutics.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Dr. Babatunde Adekunle Otulana Non-Executive Director, Senior Independent Director	-
Mr. Peter Sinclair Jensen Non-Executive Director, Chairman	-
Mr. Zheqing Simon Shen Non-Executive Director	-
Mr. Anthony Michael Parker Non-Executive Director	-
Dr. Shaun Furlong Executive Director, Chief Financial Officer	-
Mr. Manuel Llobet Executive Director, Chief Executive Officer	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Lazard Asset Management Ltd	1,038,369
Lazard Multicap UK Income Fund	1,038,369

Director dealings

Date chevron-l-regular chevron-r-regular	Action
21 Jan 2025	Purchase

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.